We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

This study is currently recruiting participants.
Verified February 2017 by Weill Medical College of Cornell University
Sponsor:
ClinicalTrials.gov Identifier:
NCT01054196
First Posted: January 22, 2010
Last Update Posted: February 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Celgene
Information provided by (Responsible Party):
Weill Medical College of Cornell University
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2025
  Estimated Primary Completion Date: December 2022 (Final data collection date for primary outcome measure)